<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
  <channel>
    <title>Featured Headlines Feed for ICPT</title>
    <link />
    <description>Headlines for Intercept Pharmaceuticals, Inc.</description>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <generator>Argotic Syndication Framework 2008.0.2.0, http://www.codeplex.com/Argotic</generator>
    <item>
      <title>Weyerhaeuser Stock Offer at 1.7% Discount; Intercept Offer Prices Flat</title>
      <link>http://www.fool.com/news/xt/smartmoney/www.smartmoney.com/news/on/.aspx?story=on-20130619-000366&amp;cid=1244</link>
      <author>Smart Money</author>
      <pubDate>Wed, 19 Jun 2013 07:23:00 GMT</pubDate>
    </item>
    <item>
      <title>Intercept Pharmaceuticals Prices  1.73M Share Offering at $33.01/Share</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/06/3688265/intercept-pharmaceuticals-prices-1-73m-share-offering-at-33-01share.aspx</link>
      <author>Benzinga</author>
      <pubDate>Wed, 19 Jun 2013 06:23:39 GMT</pubDate>
    </item>
    <item>
      <title>Intercept Pharmaceuticals Announces 1.73M Share Offering</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/06/3679965/intercept-pharmaceuticals-announces-1-73m-share-offering.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 17 Jun 2013 06:45:30 GMT</pubDate>
    </item>
    <item>
      <title>Intercept Issues Added Results of Global Primary Biliary Cirrhosis Study, Says Data Failed to Meet P</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/04/3542104/intercept-issues-added-results-of-global-primary-biliary-cirrhosis-study-says-dat.aspx</link>
      <author>Benzinga</author>
      <pubDate>Tue, 30 Apr 2013 08:17:04 GMT</pubDate>
    </item>
    <item>
      <title>Intercept Pharmaceuticals: The Risks That No One Is Talking About</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1354111-intercept-pharmaceuticals-the-risks-that-no-one-is-talking-about.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Fri, 19 Apr 2013 09:35:02 GMT</pubDate>
    </item>
    <item>
      <title>UPDATE: Wedbush Raises PT on Intercept Pharmaceuticals on Decreased Regulatory Risk</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/analyst-ratings/analyst-color/13/04/3497405/update-wedbush-raises-pt-on-intercept-pharmaceuticals-on.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 15 Apr 2013 11:48:39 GMT</pubDate>
    </item>
    <item>
      <title>Intercept's CEO Discusses Q4 2012 Results - Earnings Call Transcript</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1284671-intercept-s-ceo-discusses-q4-2012-results-earnings-call-transcript.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Mon, 18 Mar 2013 23:41:03 GMT</pubDate>
    </item>
    <item>
      <title>IPO Market Update And Outlook</title>
      <link>http://www.fool.com/news/xt/seekingalpha/seekingalpha.com/article/1143391-ipo-market-update-and-outlook.aspx</link>
      <author>Seeking Alpha</author>
      <pubDate>Wed, 30 Jan 2013 10:57:14 GMT</pubDate>
    </item>
    <item>
      <title>Intercept Pharma Begins Phase 2 NASH Trial of OCA in Japan</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/13/01/3221601/intercept-pharma-begins-phase-2-nash-trial-of-oca-in-japan.aspx</link>
      <author>Benzinga</author>
      <pubDate>Mon, 07 Jan 2013 17:35:52 GMT</pubDate>
    </item>
    <item>
      <title>5 IPOs Prove Tech Is Alive and Well</title>
      <link>http://www.fool.com/news/xt/minyanville/www.minyanville.com/sectors/technology/articles/5-ipos-prove-tech-is-alive/12/27/2012/id/46973.aspx</link>
      <author>Minyanville</author>
      <pubDate>Thu, 27 Dec 2012 11:40:00 GMT</pubDate>
    </item>
    <item>
      <title>The Top Five IPOs of 2012 — 100% Gains</title>
      <link>http://www.fool.com/news/xt/247wallst/247wallst.com/2012/12/26/the-top-five-ipos-of-2012-100-gains/.aspx</link>
      <author>247wallst</author>
      <pubDate>Wed, 26 Dec 2012 09:12:17 GMT</pubDate>
    </item>
    <item>
      <title>Intercept Pharmaceuticals Completes Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial</title>
      <link>http://www.fool.com/news/xt/benzinga/www.benzinga.com/news/12/12/3185710/intercept-pharmaceuticals-completes-enrollment-in-phase-3-primary-biliary-cirrhos.aspx</link>
      <author>Benzinga</author>
      <pubDate>Wed, 19 Dec 2012 07:07:05 GMT</pubDate>
    </item>
    <item>
      <title>Insiders Trading ICPT JNS PCS FAST</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11739938/1/insiders-trading-icpt-jns-pcs-fast.html.aspx?puc=aol&amp;cm_ven=aol</link>
      <author>TheStreet</author>
      <pubDate>Wed, 17 Oct 2012 00:00:00 GMT</pubDate>
    </item>
    <item>
      <title>Cramer's Top 5: High-Growth IPOs</title>
      <link>http://www.fool.com/news/xt/thestreet/www.thestreet.com/story/11737275/1/cramers-top-5-high-growth-ipos.html.aspx?puc=aol&amp;cm_ven=aol</link>
      <author>TheStreet</author>
      <pubDate>Tue, 16 Oct 2012 00:00:00 GMT</pubDate>
    </item>
  </channel>
</rss>
